Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan F List

Showing results (71-80 of 212) with videos related to

Pageof 22
Sort By:
Blood|September 1, 2012
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndromeRami S Komrokji, Jeffrey E Lancet, Arlene S Swern, et al.
American Journal of Hematology|June 20, 2015
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapyPatrick T Griffin, Rami S Komrokji, Carlos M De Castro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndromeAlan F List, Maria R Baer, David P Steensma, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 24, 2013
Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failureVu H Duong, Karen Lin, Tea Reljic, et al.
Cancer|September 30, 2011
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndromeRami S Komrokji, Maria Corrales-Yepez, Najla Al Ali, et al.
Blood|August 15, 2002
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phaseAlan F List, Kenneth J Kopecky, Cheryl L Willman, et al.
The Oncologist|April 12, 2011
Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based surveyMikkael A Sekeres, Jaroslaw P Maciejewski, Alan F List, et al.
British Journal of Haematology|April 29, 2006
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemiaThomas Pabst, Erica Stillner, Donna Neuberg, et al.
Blood|April 30, 2008
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programsDana E Rollison, Nadia Howlader, Martyn T Smith, et al.
Cancer Research|July 5, 2012
HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1Gisela Caceres, Robert W Robey, Lubomir Sokol, et al.
Pageof 22

Showing results (71-80 of 212) with videos related to

Sort By:
Pageof 22
Blood|September 1, 2012
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndromeRami S Komrokji, Jeffrey E Lancet, Arlene S Swern, et al.
American Journal of Hematology|June 20, 2015
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapyPatrick T Griffin, Rami S Komrokji, Carlos M De Castro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndromeAlan F List, Maria R Baer, David P Steensma, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 24, 2013
Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failureVu H Duong, Karen Lin, Tea Reljic, et al.
Cancer|September 30, 2011
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndromeRami S Komrokji, Maria Corrales-Yepez, Najla Al Ali, et al.
Blood|August 15, 2002
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phaseAlan F List, Kenneth J Kopecky, Cheryl L Willman, et al.
The Oncologist|April 12, 2011
Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based surveyMikkael A Sekeres, Jaroslaw P Maciejewski, Alan F List, et al.
British Journal of Haematology|April 29, 2006
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemiaThomas Pabst, Erica Stillner, Donna Neuberg, et al.
Blood|April 30, 2008
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programsDana E Rollison, Nadia Howlader, Martyn T Smith, et al.
Cancer Research|July 5, 2012
HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1Gisela Caceres, Robert W Robey, Lubomir Sokol, et al.
Pageof 22